Table 1.
Characteristics of patients who underwent allogeneic hematopoietic cell transplantation for the treatment of chronic myeloid leukemia from 1999-2004, reported to the CIBMTR
| Variable | n eval | First chronic phase |
n eval | Advanced phase |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Imatinib n (%) | n eval | No imatinib n (%) | P* | Imatinib n (%) | n eval | No imatinib n (%) | P | |||
| No. of patients | 185 | 675 | 224 | 225 | ||||||
| No. of centers | 63 | 71 | 56 | 59 | ||||||
| Age, y, median (range) | 185 | 38 (3-66) | 675 | 37 (2-66) | .86 | 224 | 42 (12-70) | 225 | 40 (7-70) | .04 |
| Age at transplantation, y | 185 | 675 | .44 | 224 | 225 | .37 | ||||
| ≤ 30 | 62 (34) | 202 (30) | 39 (17) | 46 (20) | ||||||
| 31-40 | 42 (23) | 193 (29) | 53 (24) | 65 (29) | ||||||
| 41-50 | 50 (27) | 177 (26) | 66 (29) | 58 (26) | ||||||
| > 50 | 31 (17) | 103 (15) | 66 (29) | 56 (25) | ||||||
| Male sex | 185 | 103 (56) | 675 | 389 (58) | .63 | 224 | 142 (63) | 225 | 138 (61) | .65 |
| White race | 185 | 152 (82) | 675 | 506 (75) | .04 | 224 | 173 (77) | 225 | 172 (76) | .84 |
| Karnofsky score at transplantation | 162 | 663 | .21 | 201 | 214 | .34 | ||||
| ≤ 80% | 12 (7) | 71 (11) | 66 (33) | 61 (29) | ||||||
| > 80% | 150 (93) | 592 (89) | 135 (67) | 153 (71) | ||||||
| Time from diagnosis to transplant, mo, median (range) | 185 | 13 (2-107) | 675 | 9 (1-126) | < .001 | 224 | 22 (1-142) | 225 | 13 (2-180) | < .001 |
| Time from diagnosis to transplantation | 185 | 675 | < .001 | 224 | 225 | < .001 | ||||
| ≤ 12 mo | 75 (41) | 457 (68) | 69 (31) | 107 (48) | ||||||
| > 12 mo | 110 (59) | 218 (32) | 155 (69) | 118 (52) | ||||||
| EBMT score | 185 | 675 | .001 | < .001 | ||||||
| 0-1 | 18 (10) | 134 (20) | 0 | 2 (1) | ||||||
| 2 | 54 (29) | 227 (34) | 2 (1) | 8 (4) | ||||||
| 3 | 67 (36) | 207 (30) | 24 (11) | 35 (15) | ||||||
| 4 | 41 (22) | 95 (14) | 48 (21) | 73 (32) | ||||||
| ≥ 5 | 5 (3) | 12 (2) | 150 (67) | 107 (48) | ||||||
| Disease stage pretransplantation | 185 | 675 | 1.0 | 224 | 225 | .65 | ||||
| First chronic phase | 185 (100) | 675 (100) | ||||||||
| Accelerated phase | 0 (0) | 0 (0) | 91 (41) | 94 (42) | ||||||
| ≥ Second chronic phase | 0 (0) | 0 (0) | 96 (43) | 88 (39) | ||||||
| Blast phase | 0 (0) | 0 (0) | 37 (17) | 43 (19) | ||||||
| Hemoglobin, g/dL | 180 | 13 (8-17) | 665 | 13 (0-18) | .52 | 173 | 11 (0-15) | 167 | 11 (0-15) | .07 |
| Platelets, 109/L | 181 | 220 (33-1568) | 559 | 264 (0-2684) | < .001 | 188 | 172 (0-1570) | 186 | 217 (12-2115) | .02 |
| White blood count, 109/L | 183 | 6 (1-141) | 662 | 9 (0-504) | < .001 | 218 | 5 (0.1-100) | 214 | 8 (0.3-165) | < .001 |
| Blasts, % | 156 | 0 (0-8) | 651 | 0 (0-22) | .0003 | 194 | 0 (0-86) | 183 | 0 (0-90) | .04 |
| Donor/recipient sex match | 185 | 675 | .85 | 224 | 225 | .91 | ||||
| Male-male | 68 (37) | 242 (36) | 93 (42) | 86 (38) | ||||||
| Male-female | 43 (23) | 154 (23) | 44 (20) | 46 (20) | ||||||
| Female-male | 35 (19) | 147 (22) | 49 (22) | 52 (23) | ||||||
| Female-female | 39 (21) | 132 (20) | 38 (17) | 41 (18) | ||||||
| Donor | 185 | 675 | < .001 | 224 | 225 | .01 | ||||
| HLA-identical sibling | 52 (28) | 290 (43) | 47 (21) | 77 (34) | ||||||
| Related | 4 (2) | 18 (3) | 7 (3) | 6 (3) | ||||||
| Unrelated | 129 (70) | 367 (54) | 170 (76) | 142 (63) | ||||||
| Donor-recipient HLA match | 185 | 675 | < .001 | 224 | 225 | < .001 | ||||
| Matched sibling | 52 (28) | 290 (43) | 47 (21) | 77 (34) | ||||||
| Well matched | 85 (46) | 135 (20) | 93 (42) | 43 (19) | ||||||
| Partially matched | 26 (14) | 135 (20) | 50 (22) | 57 (26) | ||||||
| Mismatch | 13 (7) | 82 (12) | 18 (8) | 25 (11) | ||||||
| Unknown | 9 (5) | 33 (5) | 16 (7) | 23 (10) | ||||||
| Donor-recipient cytomegalovirus status | 172 | 619 | .06 | 211 | 204 | .03 | ||||
| +/+ | 43 (25) | 211 (34) | 65 (31) | 79 (39) | ||||||
| +/− | 19 (11) | 82 (13) | 20 (9) | 31 (15) | ||||||
| −/+ | 41 (24) | 133 (21) | 65 (31) | 43 (21) | ||||||
| −/− | 69 (40) | 193 (31) | 61 (29) | 51 (25) | ||||||
| Conditioning regimen | 185 | 675 | < .001 | 224 | 225 | .71 | ||||
| Myeloablative | 143 (77) | 599 (89) | 175 (78) | 179 (80) | ||||||
| Nonmyeloablative | 42 (23) | 76 (11) | 49 (22) | 46 (20) | ||||||
| Total body irradiation | 185 | 675 | .01 | 224 | 225 | .17 | ||||
| Yes | 72 (39) | 334 (49) | 104 (46) | 119 (53) | ||||||
| No | 113 (61) | 341 (51) | 120 (54) | 106 (47) | ||||||
| Graft type | 185 | 675 | < .001 | 224 | 225 | < .001 | ||||
| Bone marrow | 100 (54) | 481 (71) | 86 (38) | 148 (66) | ||||||
| Peripheral blood | 85 (46) | 194 (29) | 138 (62) | 77 (34) | ||||||
| Year of transplantation | 185 | 675 | < .001 | 224 | 225 | < .001 | ||||
| 1999-2000 | 3 (2) | 472 (70) | 12 (5) | 141 (63) | ||||||
| 2001-2002 | 51 (28) | 163 (24) | 88 (39) | 47 (21) | ||||||
| 2003-2004 | 131 (71) | 40 (6) | 124 (55) | 37 (16) | ||||||
| GVHD prophylaxis | 185 | 675 | < .001 | 224 | 225 | < .001 | ||||
| MTX + CsA ± others | 91 (49) | 446 (66) | 104 (46) | 132 (59) | ||||||
| FK506 + MTX ± others | 55 (30) | 75 (11) | 71 (32) | 31 (14) | ||||||
| CsA ± others | 18 (10) | 75 (11) | 27 (12) | 32 (14) | ||||||
| FK506 ± others | 9 (5) | 10 (1) | 10 (4) | 6 (3) | ||||||
| T-cell depletion | 8 (4) | 51 (8) | 4 (2) | 15 (7) | ||||||
| Other† | 1 (1) | 7 (1) | 4 (2) | 5 (2) | ||||||
| None | 3 (2) | 11 (2) | 4 (2) | 4 (2) | ||||||
| Median follow-up of survivors, mo | 134 | 32 (8-86) | 421 | 69 (3-96) | 81 | 36 (13-73) | 75 | 59 (3-95) | ||
Patient-related variables include number, age, age at transplantation, sex, race, and Karnovsky score at transplantation. Disease-related variables include time from diagnosis to transplantation, EBMT score, and disease stage (pretransplantation). All remaining variables are transplantation-related.
CIBMTR indicates Center for International Blood and Marrow Transplant Research; EBMT, European Blood and Marrow Transplantation; HLA, human leukocyte antigen; GVHD, graft-versus-host disease; MTX, methotrexate; CsA, cyclosporine; FK506, tacrolimus; and HCT, hematopoietic cell transplantation.
Chi-square test for discrete covariates; Kruskal-Wallis test for continuous covariates.
Other GVHD prophylaxis (n = 17); MTX (n = 5); Tacrolimus + MTX (n = 4); Cortice Steroid + MTX (n = 3); Cellcept + MTX (n = 2); Rapamycin + MTX (n = 2); Cyclophosphamide (n = 1).